SynthesisThe American journal of gastroenterology2015
The economic impact of Clostridium difficile infection: a systematic review.
Synthesis in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.The Cochrane database of systematic reviews · 2017Pooled it
- Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.BMC infectious diseases · 2016Pooled it
- Trial
- Burden and Mortality Outcomes ofJournal of clinical medicine · 2026Article
- Article
- A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for RecurrentAntibiotics (Basel, Switzerland) · 2024Review
- The Role of Probiotics in the Prevention ofNutrients · 2024Review
- Economic Burden of Clostridioides difficile Infection in European Countries.Advances in experimental medicine and biology · 2024Article
- Article
- Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.Journal of clinical microbiology · 2022Article
- Thiol Metabolism and Volatile Metabolome ofFrontiers in microbiology · 2022Article
- Factors Associated with Clostridioides (Clostridium) Difficile Infection and Colonization: Ongoing Prospective Cohort Study in a French University Hospital.International journal of environmental research and public health · 2021Observational
- Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.Clinical drug investigation · 2021Article
- Gut microbiome andTherapeutic advances in gastroenterology · 2021Review
- Economic burden and cost-effectiveness of therapies forTherapeutic advances in gastroenterology · 2021Review
- Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection.JAMA network open · 2020Article
- The Economic Burden ofFrontiers in public health · 2020Article
- Costs of hospital-acquiredCost effectiveness and resource allocation : C/E · 2019Article
- Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
objectivesWith Clostridium difficile infection (CDI) on the rise, knowledge of the current economic burden of CDI can inform decisions on interventions related to CDI. We systematically reviewed CDI cost-of-illness (COI) studies.
methodsWe performed literature searches in six databases: MEDLINE, Embase, the Health Technology Assessment Database, the National Health Service Economic Evaluation Database, the Cost-Effectiveness Analysis Registry, and EconLit. We also searched gray literature and conducted reference list searches. Two reviewers screened articles independently. One reviewer abstracted data and assessed quality using a modified guideline for economic evaluations. The second reviewer validated the abstraction and assessment.
resultsWe identified 45 COI studies between 1988 and June 2014. Most (84%) of the studies were from the United States, calculating costs of hospital stays (87%), and focusing on direct costs (100%). Attributable mean CDI costs ranged from $8,911 to $30,049 for hospitalized patients. Few studies stated resource quantification methods (0%), an epidemiological approach (0%), or a justified study perspective (16%) in their cost analyses. In addition, few studies conducted sensitivity analyses (7%).
conclusionsForty-five COI studies quantified and confirmed the economic impact of CDI. Costing methods across studies were heterogeneous. Future studies should follow standard COI methodology, expand study perspectives (e.g., patient), and explore populations least studied (e.g., community-acquired CDI).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.